1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial

BACKGROUND: In the DISCOVER PrEP trial, emtricitabine/tenofovir alafenamide (F/TAF) was noninferior to emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV prevention. Here, we report on the renal outcomes of F/TAF and F/TDF among all DISCOVER participants and in those on baseline F/TDF PrEP...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Anthony, Workowski, Kimberly, Campbell, Thomas, Benson, Paul, Crofoot, Gordon, Salazar, Laura, Ogbuagu, Onyema, Shalit, Peter, Trottier, Benoit, Carter, Christoph C, Wong, Pamela, Brainard, Diana M, McCallister, Scott, Das, Moupali, Doblecki-Lewis, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808931/
http://dx.doi.org/10.1093/ofid/ofz359.139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808931/
http://dx.doi.org/10.1093/ofid/ofz359.139

Ejemplares similares